PTAB challenges

Proceedings overview

There is one AIA trial proceeding on file for US Patent 11129591: IPR2025-01066, which resulted in an institution denial. This outcome means that the patent's claims have not been challenged or altered through the PTAB process, indicating a stronger defensive posture for the patent owner, as the claims remain untested by this IPR.

IPR2025-01066 — Caption Health, Inc. et al. v. Purang ABOLMAESUMI et al

• Type: Inter Partes Review
• Filed: 2025-05-28
• Status: Institution Denied — The PTAB declined to institute a trial based on the petition.
• Judge panel: Lead Judge Deborah J. Katz, Administrative Patent Judge Brian J. McNamara, and Administrative Patent Judge Michael D. Tierney.
• Petition grounds: The petition challenged claims 1-18, 20-28, 39-45 of U.S. Patent No. 11,129,591 as unpatentable under 35 U.S.C. § 103 over several prior art references, specifically US 2008/0172179 to Varghese et al. ("Varghese"), US 2012/0310080 to Varghese et al. ("Varghese II"), and "Standardized Nomenclature for the Description of Cardiac Ultrasound Anatomy" by Lang et al. ("Lang").
• Institution decision: Denied — 2026-03-12. The Board determined that the Petitioner did not establish a reasonable likelihood that at least one of the challenged claims is unpatentable. The Board found that the petition failed to adequately demonstrate how the cited prior art rendered the claims obvious, particularly regarding the "view category specific quality assessment" limitations. For example, regarding claim 1, the Board found that Petitioner's arguments regarding a "quality assessment value" and its "view category specific" nature were insufficient to meet the institution threshold.
• Final Written Decision: Not issued, as institution was denied.
• Settlement / termination: N/A
• Appeal: No appeal to the Federal Circuit was filed, as there was no institution or FWD to appeal.
• Defensive value: The denial of institution means that the challenged claims (1-18, 20-28, 39-45) of US11129591 were not invalidated in this IPR. For a defendant, this indicates that these specific obviousness arguments against these claims were deemed insufficient by the PTAB, making an IPR-based defense on similar grounds potentially more challenging without significant new evidence or different legal theories.

Strategic summary

Currently, none of the claims of US Patent 11129591 have been canceled or altered through an AIA trial proceeding. The sole IPR filed, IPR2025-01066, resulted in a denial of institution, meaning the PTAB did not proceed to a full trial on the merits of unpatentability. Specifically, claims 1-18, 20-28, and 39-45 remain sustained and valid as far as the PTAB is concerned in this specific proceeding. All claims of the patent are currently SUSTAINED (in the context of not being invalidated by IPR) or UNTESTED by PTAB proceedings.

The estoppel landscape for IPR2025-01066 means that Caption Health, Inc. et al. (and any privies) are barred under 35 U.S.C. § 315(e)(2) from raising again any ground that they raised or reasonably could have raised in this petition against claims 1-18, 20-28, and 39-45. Other potential defendants, not in privy with Caption Health, Inc. et al., are not estopped by this denial. They would be free to file their own IPRs, potentially using the same prior art with different arguments, or entirely new prior art, to challenge the patent's claims. The specific prior art (Varghese, Varghese II, Lang) cited in the denied petition might still be available to other petitioners, provided they present a compelling argument for institution.

There is no discernible pattern of multiple IPRs from the same petitioner or aggressive PTAB appeals by the patent owner, as only one IPR has been filed and it did not proceed to trial. The petitioner, Caption Health, Inc. et al., appears to be a company in the medical imaging space, which aligns with the patent's subject matter. The filing of IPR2025-01066 by Caption Health, Inc. et al. suggests that they perceived a potential threat or interest in invalidating the patent. The denial indicates the initial threshold for demonstrating a reasonable likelihood of unpatentability was not met, rather than a full validation of the claims on the merits after a trial.

Recommended next steps

For a potential defendant currently facing assertion of US11129591, it's important to understand that the claims challenged in IPR2025-01066 (claims 1-18, 20-28, 39-45) have not been canceled by the PTAB. The institution decision for IPR2025-01066, available on the USPTO PTAB Decisions portal, details why the Board found the petition insufficient.

Specifically, the Board found that "Petitioner does not adequately explain how a person of ordinary skill in the art would have understood Varghese, Varghese II, and Lang to teach or suggest the claimed ‘view category specific quality assessment’ or how these references would have motivated such a combination." This reasoning highlights a potential weakness in the prior art arguments presented and suggests that any future IPR petition would need to carefully address how the prior art discloses or renders obvious the "view category specific quality assessment" and its "suitability for quantified clinical measurement of anatomical features" limitations, especially for the independent claims.

Given the institution denial, if a defendant plans to pursue an IPR strategy, they should:

1. Carefully review the IPR2025-01066 Institution Decision to understand the specific deficiencies identified by the Board.
2. Conduct a robust prior art search to identify new and stronger prior art references that more clearly teach or suggest the distinguishing features of the challenged claims, particularly the "view category specific quality assessment" aspect.
3. Develop detailed claim constructions and obviousness arguments that explicitly overcome the Board's reasoning for denial in IPR2025-01066. This would involve a thorough mapping of prior art elements to each claim limitation and a clear articulation of the motivation to combine references.
4. Consider challenging different claims if a viable strategy exists, or focusing on claims not addressed in the denied IPR (though in this case, a broad set of claims was challenged).